EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression

Xiangyu Yao, Songfan Wang, Jin Xie iD, Fei Chen iD, Hongxia Qiu, Gang Li, Zhenze Jiang, Weixing Zhang, Xiaoxiao Jiang iD, Jianguo Chen, Xin Shu, Dan Zhao iD und 12 weitere

Proceedings of the National Academy of Sciences · 10.11.2026 · 123 (45)

DOI: 10.1073/pnas.2621263123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.11.2026. Verfasst von Xiangyu Yao und 23 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Discovery Department, China Innovation Center of Roche, Shanghai 201203, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Antineoplastic Agents. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical durability of first-generation KRAS G12C inhibitors is constrained by resistance mechanisms, primarily the rapid, receptor tyrosine kinase (RTK)-mediated reactivation of KRAS to its drug-insensitive, guanosine triphosphate (GTP)-bound (ON) state. Here, we perform a systematic comparative characterization of clinical and investigational KRAS G12C inhibitors, including Sotorasib, Adagrasib, Divarasib, and Elironrasib, and our structurally optimized tricomplex ON inhibitor, RO7783903 (RO3903). We demonstrate that the covalent tricomplex inhibitors RO3903 and Elironrasib effectively outpace dynamic nucleotide cycling, conferring resilience to potent RTK stimulation and overcoming the secondary KRAS mutations that drive clinical resistance to guanosine diphosphate (GDP)-bound (OFF) state inhibitors. Notably, RO3903 potently inhibits tumor growth in a dose-dependent manner across multiple preclinical models, including an orthotopic intracranial model. Furthermore, RO3903 exhibits synergistic efficacy when combined with inhibitors targeting OFF-state KRAS G12C, YAP-TEAD, EGFR/MET, or FAK, as well as with anti-PD1 antibody and anti-PD1/VEGF bispecific antibody immunotherapies. The high potency, fast target engagement, and brain tumor inhibition of RO3903 position this molecule as a valuable tool reagent and a promising partner for combination strategies to achieve durable tumor regression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Drug Resistance, NeoplasmAntineoplastic AgentsAnimalsHumansMiceCell Line, TumorXenograft Model Antitumor AssaysMutation

Stichwörter der Autor:innen

KRAS G12C tricomplex inhibitoradaptive resistancecombination therapytarget engagement

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Oncology Discovery Department, China Innovation Center of Roche, Shanghai 201203, China.
  • Lead Discovery Department, China Innovation Center of Roche, Shanghai 201203, China.
  • Pharmaceutical Sciences Department, China Innovation Center of Roche, Shanghai 201203, China.
  • AI, Data and Digital Department, China Innovation Center of Roche, Shanghai 201203, China.
  • Medicinal Chemistry Department, China Innovation Center of Roche, Shanghai 201203, China.

ORCID-Profile: Jin Xie, Fei Chen, Xiaoxiao Jiang, Dan Zhao, Yuying Bian, Shuai Chen, Zhipeng Yan, Wei Zhu, Hong Shen, Xinyi Huang, Chiho Li, Beimeng Yang

Zitieren

APA

Yao, X., Wang, S., Xie, J., Chen, F., Qiu, H., Li, G., Jiang, Z., Zhang, W., Jiang, X., Chen, J., Shu, X., Zhao, D., Li, Y., Bian, Y., Huang, K., Jin, L., Chen, S., Yan, Z., Liu, H., …, & Yang, B. (2026). Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression. Proceedings of the National Academy of Sciences, 123(45). https://doi.org/10.1073/pnas.2621263123

Vancouver

Yao X, Wang S, Xie J, Chen F, Qiu H, Li G, et al. Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression. Proceedings of the National Academy of Sciences. 2026;123(45). doi:10.1073/pnas.2621263123

BibTeX
@article{Yao2026,
  author = {Yao, Xiangyu and Wang, Songfan and Xie, Jin and Chen, Fei and Qiu, Hongxia and Li, Gang and Jiang, Zhenze and Zhang, Weixing and Jiang, Xiaoxiao and Chen, Jianguo and Shu, Xin and Zhao, Dan and Li, Yumeng and Bian, Yuying and Huang, Ke and Jin, Litian and Chen, Shuai and Yan, Zhipeng and Liu, Haixia and Zhu, Wei and Shen, Hong and Huang, Xinyi and Li, Chiho and Yang, Beimeng},
  title = {Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {45},
  doi = {10.1073/pnas.2621263123}
}
Kostenlos starten →